AbCellera prices $200M follow-on offering at $9.75/share, a 5.9% discount to prior close

Filed August 13, 2026 · ~1 min read

Key Changes

• high

  AbCellera priced 20.5 million common shares and pre-funded warrants at $9.75 per share, raising $200 million gross ($188 million net after underwriting fees). All proceeds go to the company; no selling stockholders.

  The Offering verify on EDGAR →
• high

  Net proceeds of ~$187 million will fund ABCL635 clinical program, internal pipeline R&D, and general corporate purposes. The company retains broad discretion to redirect proceeds.

  Use of Proceeds verify on EDGAR →
• high

  New investors face immediate dilution of $6.67 per share (68% of the offering price), as the $9.75 price substantially exceeds the company's $2.65 net tangible book value per share as of June 30, 2026.

  Dilution verify on EDGAR →